Gilead Sciences (GILD) Competitors

Biogen (NASDAQ:BIIB) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings, community ranking and risk.

Which has preferable earnings and valuation, BIIB or GILD?

Gilead Sciences has higher revenue and earnings than Biogen. Gilead Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.84B	2.82	$1.16B	$7.98	23.87
Gilead Sciences	$27.12B	3.04	$5.67B	$4.50	14.70

Does the MarketBeat Community prefer BIIB or GILD?

Gilead Sciences received 674 more outperform votes than Biogen when rated by MarketBeat users. Likewise, 77.46% of users gave Gilead Sciences an outperform vote while only 71.88% of users gave Biogen an outperform vote.

Company	Underperform	Outperform
Biogen	Outperform Votes 1769 71.88%	Underperform Votes 692 28.12%
Gilead Sciences	Outperform Votes 2443 77.46%	Underperform Votes 711 22.54%

Which has more volatility and risk, BIIB or GILD?

Biogen has a beta of -0.02, suggesting that its stock price is 102% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500.

Does the media refer more to BIIB or GILD?

In the previous week, Biogen had 9 more articles in the media than Gilead Sciences. MarketBeat recorded 29 mentions for Biogen and 20 mentions for Gilead Sciences. Biogen's average media sentiment score of 0.80 beat Gilead Sciences' score of 0.19 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	5 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	7 Negative mention(s)	1 Very Negative mention(s)	Neutral
Gilead Sciences	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer BIIB or GILD?

Biogen currently has a consensus target price of $296.35, indicating a potential upside of 55.55%. Gilead Sciences has a consensus target price of $84.71, indicating a potential upside of 28.04%. Given Gilead Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Biogen is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	0 Sell rating(s)	9 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.67
Gilead Sciences	1 Sell rating(s)	9 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.27

Is BIIB or GILD more profitable?

Gilead Sciences has a net margin of 20.89% compared to Gilead Sciences' net margin of 11.81%. Biogen's return on equity of 38.85% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	11.81%	14.91%	8.18%
Gilead Sciences	20.89%	38.85%	13.60%

Do insiders and institutionals have more ownership in BIIB or GILD?

87.9% of Biogen shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 0.6% of Biogen shares are held by company insiders. Comparatively, 0.2% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Gilead Sciences beats Biogen on 10 of the 18 factors compared between the two stocks.